Sachetta LLC Lowers Holdings in Merck & Co., Inc. $MRK

Sachetta LLC lessened its stake in Merck & Co., Inc. (NYSE:MRK) by 69.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,972 shares of the company’s stock after selling 4,578 shares during the quarter. Sachetta LLC’s holdings in Merck & Co., Inc. were worth $208,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently modified their holdings of MRK. DLD Asset Management LP raised its position in shares of Merck & Co., Inc. by 30.1% in the 3rd quarter. DLD Asset Management LP now owns 47,500,000 shares of the company’s stock worth $3,986,675,000 after purchasing an additional 11,000,000 shares during the last quarter. Jennison Associates LLC purchased a new position in shares of Merck & Co., Inc. in the 4th quarter worth about $585,192,000. Invesco Ltd. raised its position in shares of Merck & Co., Inc. by 16.6% in the 3rd quarter. Invesco Ltd. now owns 19,844,936 shares of the company’s stock worth $1,665,585,000 after purchasing an additional 2,821,766 shares during the last quarter. Ameriprise Financial Inc. raised its position in shares of Merck & Co., Inc. by 20.7% in the 3rd quarter. Ameriprise Financial Inc. now owns 15,933,909 shares of the company’s stock worth $1,336,877,000 after purchasing an additional 2,735,459 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Merck & Co., Inc. by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 254,322,763 shares of the company’s stock worth $26,770,014,000 after purchasing an additional 2,185,853 shares during the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Q1 results beat expectations — Merck posted revenue and adjusted EPS above Street forecasts with Keytruda and Winrevair driving growth; the beats and upbeat commentary lifted investor sentiment. Merck tops Q1 estimates
• Positive Sentiment: Regulatory approvals & pipeline progress expand addressable markets — Merck won FDA approval for a new 2‑drug HIV regimen (IDVYNSO) and EC approval for ENFLONSIA for RSV prevention; the company also dosed the first patient in Phase 3 enpatoran lupus trials, adding long‑term growth optionality. Merck expands beyond oncology
• Neutral Sentiment: Analyst action mixed — Wells Fargo trimmed its price target to $145 but kept an Overweight rating, signaling continued confidence despite a modestly lower PT. Wells Fargo lowers PT
• Neutral Sentiment: FY‑2026 guidance and outlook — Merck provided EPS guidance of $5.04–$5.16 and a narrowed sales view ($65.8B–$67.0B). Guidance is close to consensus but tighter ranges mean less revenue upside visibility near term. Merck Q1 financial results
• Neutral Sentiment: Sector context — Biotech peers are mixed (Moderna saw vaccine revenue rebound but its stock fell; Organon missed), so some moves reflect broader healthcare rotation rather than Merck‑specific news. Moderna Covid vaccine drives growth
• Negative Sentiment: Acquisition-related charge produced a GAAP loss — A Cidara-related charge drove a quarterly GAAP loss, which clouds headline profitability despite the operational beat. Merck posts quarterly loss due to Cidara charge
• Negative Sentiment: Longer-term growth risks flagged — Coverage noted potential future pressure from lost sales on some products (e.g., competitive threats to Keytruda, HPV and diabetes medicines) and Merck said it is working on mitigations. That risk keeps some investors cautious. Merck stock falls after earnings

Analyst Ratings Changes

MRK has been the subject of several recent analyst reports. Cantor Fitzgerald lifted their price target on Merck & Co., Inc. from $116.00 to $120.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 4th. Citigroup boosted their target price on Merck & Co., Inc. from $120.00 to $125.00 and gave the stock a “neutral” rating in a research report on Friday, March 20th. Guggenheim boosted their target price on Merck & Co., Inc. from $122.00 to $140.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. Deutsche Bank Aktiengesellschaft raised Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 target price for the company in a research report on Friday, February 13th. Finally, Barclays started coverage on Merck & Co., Inc. in a research report on Friday, February 20th. They issued an “overweight” rating and a $140.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $128.18.

Insiders Place Their Bets

In other Merck & Co., Inc. news, EVP Richard R. Deluca sold 37,685 shares of the business’s stock in a transaction dated Friday, February 6th. The stock was sold at an average price of $120.92, for a total transaction of $4,556,870.20. Following the completion of the sale, the executive vice president directly owned 160,174 shares in the company, valued at $19,368,240.08. The trade was a 19.05% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CMO Chirfi Guindo sold 20,000 shares of the business’s stock in a transaction dated Thursday, February 5th. The shares were sold at an average price of $121.88, for a total value of $2,437,600.00. Following the sale, the chief marketing officer owned 80,615 shares of the company’s stock, valued at approximately $9,825,356.20. This represents a 19.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 320,176 shares of company stock worth $38,281,735 in the last quarter. Insiders own 0.17% of the company’s stock.

Merck & Co., Inc. Price Performance

Shares of NYSE:MRK opened at $112.30 on Friday. Merck & Co., Inc. has a fifty-two week low of $73.31 and a fifty-two week high of $125.14. The business has a 50-day simple moving average of $117.69 and a two-hundred day simple moving average of $107.54. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.30 and a current ratio of 1.54. The firm has a market cap of $277.36 billion, a price-to-earnings ratio of 31.63, a price-to-earnings-growth ratio of 2.27 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 26.84% and a net margin of 13.59%.The business had revenue of $16.29 billion during the quarter, compared to analyst estimates of $15.85 billion. During the same quarter in the previous year, the firm earned $2.22 EPS. Merck & Co., Inc.’s revenue was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, analysts expect that Merck & Co., Inc. will post 4.9 earnings per share for the current year.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.